Valcyte 2014 U.S. PROMOTIONAL AUDIT REPORT

Published July 2015 • 27 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Valcyte through personal promotion in 2014 to drive use within the Cytomegalovirus Infection market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Genentech’s depth of coverage vary within key specialties (e.g., Nephrology, Transplant Surgery, General Surgery, Pediatric Medicine, Gastroenterology, and Internal Medicine) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Valcyte throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Valcyte in 2014?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 400 paid interactions across 200 physicians made on behalf of Valcyte were carefully examined to support our analysis.